A Major Energy Company is Formed…
Attention traders: It’s Monday Morning and our Lead Trading Tactician Nate Bear is giving you his weekly stocks to watch. Click the image below to see why he believes this is a day trader’s market right now.
Good morning Wake-up Watchlisters! While you’re sipping coffee you’ll see stock futures as investors remained optimistic that US politicians would be able to resolve the debt-ceiling standoff. President Joe Biden expressed hope that a deal could be reached, and S&P 500 futures climbed 0.4% after Friday’s retreat. Copper and mining shares also advanced, and South Africa’s rand gained on signs of a thaw in the country’s diplomatic row with the US. Despite the focus on the US debt ceiling this week, strategists have warned of economic disaster and market turmoil if politicians fail to agree to raise the government’s $31.4 trillion borrowing limit.
The volatile markets had nothing on The War Room last week. Despite drama surrounding the debt ceiling uncertainty, we posted a 100% win rate including a double digit winner on PYPL in one trading day.
Here’s a look at the top-moving stocks this morning.
Magellan Midstream Partners L.P. (NYSE: MMP)
Magellan Midstream Partners is up 11.62% premarket after Oneok agreed to acquire the company in an $18.8 billion cash-and-stock deal, creating one of the largest oil and natural gas pipeline operators in the US. Each Magellan stakeholder will receive $25 in cash and 0.6670 shares of Oneok stock per unit. The acquisition includes $8.8 billion in new equity and the assumption of $5 billion of existing net debt. The deal will provide Oneok access to a network of crude oil and refined products conduits and terminals extending from Texas to Minnesota. The combined company will have a total enterprise value of $60 billion, making it one of the five largest US pipeline operators.
The recent oil and gas surge has created a unique investment opportunity outside the stock market, and our friend Marc Lichtenfeld is telling readers exactly how to play it.
Sarepta Therapeutics (Nasdaq: SRPT)
Sarepta Therapeutics is up 28.24% premarket after reporting FDA advisors voted in support of Sarepta Therapeutics’ highly anticipated gene therapy to treat Duchenne muscular dystrophy, a muscle-wasting disease caused by the absence of the dystrophin protein. The gene therapy produces a shortened form of that protein, called microdystrophin. While the FDA is not bound by the panel’s recommendation, it does take it into account. The panelists offered mixed views, with some indicating that the drug works and others saying there isn’t enough statistical evidence. One panelist cited videos from parents of children enrolled in the study, which showed improvement in the patients’ ability to stand, jump, run, and climb.
Those are the biggest stock movers for today.
The Wake-Up Watchlist Research Team